Pain characteristics in patients with unexplained chest pain and patients with ischemic heart disease.

The Sahlgrenska Academy at Göteborg University, Institute of Health and Care Sciences, Box 457, SE-40530 Göteborg, Sweden.
European Journal of Cardiovascular Nursing (Impact Factor: 2.04). 06/2007; 6(2):130-6. DOI: 10.1016/j.ejcnurse.2006.06.003
Source: PubMed

ABSTRACT Little scientific attention has been paid to providing a comprehensive multidimensional description of chest pain in patients with unexplained chest pain.
The aims of the present study were: (1) to describe the symptom chest pain, including the dimensions of intensity, quality, duration and location in patients with unexplained chest pain (UCP); and (2) to identify similarities and differences in how patients with UCP and patients with ischemic heart disease (IHD) describe chest pain.
A descriptive, correlational and comparative design. Totally 208 consecutive UCP patients and 40 IHD patients below 70 years of age participated. Pain was assessed using the instrument Pain-O-Meter.
The occurrence of chest pain was 79% (n=165) in UCP patients versus 60% (n=22) in the IHD patients (p=0.001). Patients with UCP reported greater pain intensity and used more sensory and affective words than IHD patients (p<0.01). Relationships between pain location and amount of body surface involved in the pain and pain intensity in both groups were found (p<0.001).
Our results showed some defining characteristics of the UCP group, but the many similarities between the two groups in their experience of chest pain made it impossible to clearly differentiate the groups' pain profiles.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of noncardiac chest pain (NCCP) remains a challenge. This is in part due to the heterogeneous nature of this disorder. Several conditions are associated with NCCP including gastro-oesophageal reflux disease (GERD), oesophageal dysmotility, oesophageal hypersensitivity as well as others. To determine the currently available therapeutic modalities for NCCP. We performed a systematic review of the literature that was published between January, 1980 and March, 2011. We identified 734 studies; 68 of them met entry criteria. Patients with GERD-related NCCP should receive proton pump inhibitors (PPI) twice daily for at least 8 weeks. Smooth muscle relaxants are only recommended for temporary relief of NCCP with motility disorders. Botulinum toxin injection of the distal oesophagus may be effective in the treatment of NCCP and spastic oesophageal motility disorders. Studies assessing the value of tricyclic antidepressants, trazodone and selective serotonin reuptake inhibitors in NCCP are relatively small, but suggest an oesophageal analgesic effect in NCCP patients that is limited by their side effects profile. The usage of theophylline to treat patients with non-GERD-related NCCP should be weighed against its potential toxicity. Use of complementary medicine has been scarcely studied in NCCP. Patients with coexisting psychological morbidity or those not responding to any medical therapy should be considered for psychological intervention. Cognitive behavioural therapy and hypnotherapy may be useful in the treatment of NCCP. Patients with GERD-related noncardiac chest pain should be treated with at least double dose PPI. The primary treatment for non-GERD-related noncardiac chest pain, regardless if oesophageal dysmotility is present, is pain modulators.
    Alimentary Pharmacology & Therapeutics 11/2011; 35(1):5-14. · 4.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To determine the diagnostic value of single symptoms and signs for coronary heart disease (CHD) in patients with chest pain. Methods. Searches of two electronic databases (EMBASE 1980 to March 2008, PubMed 1966 to May 2009) and hand searching in seven journals were conducted. Eligible studies recruited patients presenting with acute or chronic chest pain. The target disease was CHD, with no restrictions regarding case definitions, eg, stable CHD, acute coronary syndrome (ACS), acute myocardial infarction (MI), or major cardiac event (MCE). Diagnostic tests of interest were items of medical history and physical examination. Bivariate random effects model was used to derive summary estimates of positive (pLR) and negative likelihood ratios (nLR). Results. We included 172 studies providing data on the diagnostic value of 42 symptoms and signs. With respect to case definition of CHD, diagnostically most useful tests were history of CHD (pLR=3.59), known MI (pLR=3.21), typical angina (pLR=2.35), history of diabetes mellitus (pLR=2.16), exertional pain (pLR=2.13), history of angina pectoris (nLR=0.42), and male sex (nLR=0.49) for diagnosing stable CHD; pain radiation to right arm/shoulder (pLR=4.43) and palpitation (pLR=0.47) for diagnosing MI; visceral pain (pLR=2.05) for diagnosing ACS; and typical angina (pLR=2.60) and pain reproducible by palpation (pLR=0.13) for predicting MCE. Conclusions. We comprehensively reported the accuracy of a broad spectrum of single symptoms and signs for diagnosing myocardial ischemia. Our results suggested that the accuracy of several symptoms and signs varied in the published studies according to the case definition of CHD.
    Croatian Medical Journal 10/2012; 53(5):432-41. · 1.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chest pain is a common and frightening symptom. Once cardiac disease has been excluded, an esophageal source is most likely. Pathophysiologically, gastroesophageal reflux disease (GERD), esophageal dysmotility, esophageal hypersensitivity and anxiety disorders have been implicated. Treatment however remains a challenge. Here, we examined the efficacy and safety of various commonly used modalities for treatment of esophageal (non-cardiac) chest pain (ECP) and provided evidence-based recommendations. We reviewed the English literature for drug trials evaluating treatment of ECP in PUBMED, COCHRANE and MEDLINE databases from 1968 to 2012. Standard forms were used to abstract data regarding study design, duration, outcome measures and adverse events and study quality. Thirty five studies comprising of various treatments were included and grouped under five broad catagories. Patient inclusion criteria were extremely variable and studies were generally small with methodological concerns. There was good evidence to support the use of omeprazole, and fair evidence for lansoprazole, rabeprazole, theophylline, sertraline, trazodone, venlafaxine, imipramine and cognitive behavioral therapy (CBT). There was poor evidence for nifedipine, diltiazem, paroxetine, biofeedback therapy, ranitidine, nitrates, botulinum toxin, esophageal myotomy and hypnotherapy. Ideally, treatment of ECP should be aimed at correcting the underlying mechanism(s) and relieving symptoms. PPIs, antidepressants, theophylline and CBT appear to be useful for the treatment of ECP. However, there is urgent and unmet need for effective treatments and for rigorous, randomized controlled trials.
    Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 08/2013; · 5.64 Impact Factor